A randomized phase 2 study comparing different dose-approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Acronyms RE-ARRANGE
- 24 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 08 Sep 2017 According to the Trial design presented at the 42nd European Society for Medical Oncology Congress,160 of 295 planned pa- tients have been recruited at the end of March 2017 (first patient 15 July 2016).